Answers are grounded in this paper and cite their sources.
Current findings demonstrate BEX2 regulates stemness in colorectal cancer, suggesting new therapeutic targets.
Taken together, the current study findings highlight BEX2 and MCL1 as potential therapeutic targets in CRC with BEX2 emerging as a key regulator of stemness, chemoresistance, and invasiveness. These findings advance our understanding of CRC and pave the way for more effective therapies.
No takes yet. Share an insight, caveat, or question.
Qian et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: